Prestige Consumer Healthcare Q1 revenue $269.2M (+17.3%), EPS $1.14 (+32.5%); raises FY22 outlook

Prestige Consumer Healthcare Inc.

2022-Q1 EPS reported $1.14 revenue$269,181,000

Revenue $269.2M, up 17.3% YoY; diluted EPS $1.14, up 32.5% vs prior year.
North American OTC revenue $242.4M; International OTC $26.8M, up 43% from $18.7M.
Raising FY22 guidance: revenue ~$1.045B+ (prev. $957-962M), adj. EPS $3.90+ (prev. $3.58+).
TheraTears acquisition closed July 1, expected to add ~$40M revenue and $0.07 EPS to FY22.
Net cash from ops $69.3M, free cash flow $67.8M; net debt ~$1.4B; refinanced term loan to 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.